F Salvo1, K Dorjee2, K Dierberg3, W Cronin4, T D Sadutshang2, G B Migliori5, C Rodrigues6, F Trentini7, C Di Serio7, R Chaisson3, D M Cirillo1. 1. Emerging Pathogens Unit, San Raffaele Scientific Institute, Milan, Italy. 2. Tibetan Delek Hospital, Central Tibetan Administration, Dharamsala, India. 3. Division of Infectious Diseases, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 4. Maryland Department of Health and Mental Hygiene, Baltimore, Maryland, USA. 5. WHO Collaborating Centre for TB and Lung Diseases, Fondazione S Maugeri, Care and Research Institute, Tradate, Italy. 6. Department of Microbiology, Parmanand Deepchand Hinduja Hospital and Medical Research Centre, Mumbai, India. 7. University Center for Statistics in the Biomedical Sciences, Università Vita-Salute San Raffaele, Milan, Italy.
Abstract
SETTING: Tuberculosis (TB) is a major health problem among Tibetans living in exile in India. Although drug-resistant TB is considered common in clinical practice, precise data are lacking. OBJECTIVE: To determine the proportion of drug-resistant cases among new and previously treated Tibetan TB patients. DESIGN: In a drug resistance survey in five Tibetan settlements in India, culture and drug susceptibility testing (DST) for first-line drugs were performed among all consecutive new and previously treated TB cases from April 2010 to September 2011. DST against kanamycin (KM), ethionamide, para-aminosalicylic acid and ofloxacin (OFX) was performed on multidrug-resistant TB (MDR-TB) isolates. RESULTS: Of 307 patients enrolled in the study, 264 (193 new and 71 previously treated) were culture-positive and had DST available. All patients tested for the human immunodeficiency virus (n = 250) were negative. Among new TB cases, 14.5% had MDR-TB and 5.7% were isoniazid (INH) monoresistant. Among previously treated cases, 31.4% had MDR-TB and 12.7% were INH-monoresistant. Of the MDR-TB isolates, 28.6% of new and 26.1% of previously treated cases were OFX-resistant, while 7.1% of new cases and 8.7% of previously treated cases were KM-resistant. Three patients had extensively drug-resistant TB. CONCLUSIONS: MDR-TB is common in new and previously treated Tibetans in India, who also show additional complex resistance patterns. Of particular concern is the high percentage of MDR-TB strains resistant to OFX, KM or both.
SETTING:Tuberculosis (TB) is a major health problem among Tibetans living in exile in India. Although drug-resistant TB is considered common in clinical practice, precise data are lacking. OBJECTIVE: To determine the proportion of drug-resistant cases among new and previously treated Tibetan TB patients. DESIGN: In a drug resistance survey in five Tibetan settlements in India, culture and drug susceptibility testing (DST) for first-line drugs were performed among all consecutive new and previously treated TB cases from April 2010 to September 2011. DST against kanamycin (KM), ethionamide, para-aminosalicylic acid and ofloxacin (OFX) was performed on multidrug-resistant TB (MDR-TB) isolates. RESULTS: Of 307 patients enrolled in the study, 264 (193 new and 71 previously treated) were culture-positive and had DST available. All patients tested for the human immunodeficiency virus (n = 250) were negative. Among new TB cases, 14.5% had MDR-TB and 5.7% were isoniazid (INH) monoresistant. Among previously treated cases, 31.4% had MDR-TB and 12.7% were INH-monoresistant. Of the MDR-TB isolates, 28.6% of new and 26.1% of previously treated cases were OFX-resistant, while 7.1% of new cases and 8.7% of previously treated cases were KM-resistant. Three patients had extensively drug-resistant TB. CONCLUSIONS: MDR-TB is common in new and previously treated Tibetans in India, who also show additional complex resistance patterns. Of particular concern is the high percentage of MDR-TB strains resistant to OFX, KM or both.
Authors: Grant Theron; Helen E Jenkins; Frank Cobelens; Ibrahim Abubakar; Aamir J Khan; Ted Cohen; David W Dowdy Journal: Lancet Date: 2015-10-26 Impact factor: 79.321
Authors: Kevin P Cain; Nina Marano; Maureen Kamene; Joseph Sitienei; Subroto Mukherjee; Aleksandar Galev; John Burton; Orkhan Nasibov; Jackson Kioko; Kevin M De Cock Journal: PLoS Med Date: 2015-02-24 Impact factor: 11.069
Authors: Malik M Parmar; Kuldeep Singh Sachdeva; Puneet K Dewan; Kiran Rade; Sreenivas A Nair; Rashmi Pant; Sunil D Khaparde Journal: PLoS One Date: 2018-04-11 Impact factor: 3.240